Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.

Dimopoulos MA, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, Mitsouli C, Papanastasiou C, Margaritis D, Tokmaktsis A, Katodritou I, Kokkini G, Terpos E, Vyniou N, Tzilianos M, Chatzivassili A, Kyrtsonis MC, Panayiotidis P, Maniatis A; Greek Myeloma Study Group.

Ann Oncol. 2003 Jul;14(7):1039-44.

PMID:
12853344
2.

Role of liposomal anthracyclines in the treatment of multiple myeloma.

Hussein MA, Anderson KC.

Semin Oncol. 2004 Dec;31(6 Suppl 13):147-60. Review.

PMID:
15717741
3.
4.

Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma.

Moreau P.

Expert Rev Anticancer Ther. 2009 Jul;9(7):885-90. doi: 10.1586/era.09.52. Review.

PMID:
19589027
5.

New treatment strategies for multiple myeloma.

Hussein MA.

Semin Hematol. 2004 Oct;41(4 Suppl 7):2-8. Review.

PMID:
15768473
6.

[Trials of modulating the MDR1 phenotype in malignant hemopathies].

Marie JP, Zhou D, Delmer A, Zittoun R.

Bull Cancer. 1994 Dec;81 Suppl 2:88s-90s. Review. French.

PMID:
7727868
7.

Management of refractory myeloma: a review.

Buzaid AC, Durie BG.

J Clin Oncol. 1988 May;6(5):889-905. Review.

PMID:
2452861
8.

Management of renal dysfunction in multiple myeloma.

Pandit SR, Vesole DH.

Curr Treat Options Oncol. 2003 Jun;4(3):239-46. Review.

PMID:
12718801

Supplemental Content

Support Center